Lithium Ion

Lithium Ion

SCHEMBL6446186

CC(C)[C@H](NC(=O)OCCN1CCOCC1)C(=O)[O-].[Li+]

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
ATM Q13315 1/20 0.41
ACACB O00763 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TSHR P16473 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
LMNA P02545 2/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL7270236 0.88 HRH3 (0.41) ACACBHRH3KMT2A
SCHEMBL6444920 0.86 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDATMACACB
SCHEMBL6444915 0.86 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDATMACACB
SCHEMBL6448199 0.86 TDP1 (0.45) ALDH1A1KDM4EHPGDATMACACB
SCHEMBL6448194 0.86 TDP1 (0.45) ALDH1A1KDM4EHPGDATMACACB
SCHEMBL6446187 0.85 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDATMACACB
SCHEMBL6446180 0.85 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDATMACACB
SCHEMBL25669794 0.82 HRH3 (0.50) ALDH1A1KDM4EHPGDATMACACB
SCHEMBL18427273 0.77 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDATMACACB
SCHEMBL12363731 0.74 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0839798-B1 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LAB (US) 2005-08-17 EP disclosed
EP-0402646-B1 Retroviral protease inhibiting compounds ABBOTT LAB (US) 1998-07-22 EP disclosed
EP-0839798-A2 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LABORATORIES (US) 1998-05-06 EP disclosed
US-5670675-A Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1997-09-23 US disclosed
US-5545750-A TREATING HUMAN IMMUNODEFICIENCY VIRUS ABBOTT LABORATORIES (US) 1996-08-13 US disclosed
US-5142056-A Human immunodeficiency virus protease inhibitor ABBOTT LABORATORIES (US) 1992-08-25 US disclosed
EP-0402646-A1 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1990-12-19 EP disclosed